The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Defining "cisplatin ineligible" patients with metastatic bladder cancer.
Matt D. Galsky
No relevant relationships to disclose
Noah M. Hahn
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Guru Sonpavde
No relevant relationships to disclose
William K. Oh
No relevant relationships to disclose
Robert Dreicer
No relevant relationships to disclose
Nicholas J. Vogelzang
No relevant relationships to disclose
Cora N. Sternberg
No relevant relationships to disclose
Dean F. Bajorin
No relevant relationships to disclose
Joaquim Bellmunt
No relevant relationships to disclose